KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Acquires 14,562 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was purchased at an average cost of $9.22 per share, for a total transaction of $134,261.64. Following the purchase, the insider now owns 5,012,796 shares of the company’s stock, valued at $46,217,979.12. The trade was a 0.29 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, January 30th, Venrock Healthcare Capital Par acquired 43,707 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $8.76 per share, with a total value of $382,873.32.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV opened at $9.22 on Tuesday. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $16.88. The company has a market capitalization of $455.65 million, a PE ratio of -2.53 and a beta of 0.85. The business’s fifty day moving average is $8.81 and its 200 day moving average is $10.81.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. On average, sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on KALV. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. JMP Securities initiated coverage on KalVista Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $19.00 target price on the stock. Bank of America assumed coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, TD Cowen initiated coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, KalVista Pharmaceuticals presently has an average rating of “Buy” and an average target price of $23.80.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several large investors have recently added to or reduced their stakes in KALV. Vestal Point Capital LP boosted its stake in shares of KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after purchasing an additional 1,700,000 shares during the period. State Street Corp boosted its holdings in shares of KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after purchasing an additional 515,179 shares during the period. Emerald Advisers LLC lifted its holdings in shares of KalVista Pharmaceuticals by 29.8% in the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after buying an additional 192,091 shares during the period. Readystate Asset Management LP purchased a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter worth approximately $2,084,000. Finally, Emerald Mutual Fund Advisers Trust raised its stake in KalVista Pharmaceuticals by 23.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after buying an additional 121,615 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).